|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Investments, at fair value | ||||||||||||||||
| Non-controlled/unaffiliated | ||||||||||||||||
| Non-controlled/affiliated | ||||||||||||||||
| Controlled/affiliated | ||||||||||||||||
| Total investments, at fair value | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Money Market Funds | ||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Foreign currency, at fair value (cost—$2 and $27, respectively) | ||||||||||||||||
| Receivable for investments sold and repaid | ||||||||||||||||
| Income receivable | ||||||||||||||||
| Unrealized appreciation on foreign currency forward contracts | ||||||||||||||||
| Deferred financing costs | ||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities | ||||||||||||||||
| Payable for investments purchased | ||||||||||||||||
| Debt (net of deferred financing costs and discount of $50 and $45, respectively) | ||||||||||||||||
| Unrealized depreciation on foreign currency forward contracts | ||||||||||||||||
| Stockholder distributions payable | ||||||||||||||||
| Management fees payable | ||||||||||||||||
| Subordinated income incentive fees payable | ||||||||||||||||
| Administrative services expense payable | ||||||||||||||||
| Interest payable | ||||||||||||||||
| Other accrued expenses and liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Preferred stock, $0.001 par value per share, 50,000,000 shares authorized, respectively; 6,000,000 and 0 Cumulative Convertible Perpetual Preferred Stock, Series A shares, $0.001 par value per share, $25.00 liquidation preference per share, issued and outstanding, respectively | ||||||||||||||||
| Stockholders’ equity | ||||||||||||||||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding | ||||||||||||||||
| Common stock, $0.001 par value per share, 750,000,000 shares authorized, respectively, 279,688,633 and 280,066,433 shares issued and outstanding, respectively | ||||||||||||||||
| Capital in excess of par value | ||||||||||||||||
| Retained earnings (accumulated deficit) | ||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||
| Total liabilities, preferred stock and stockholders’ equity | ||||||||||||||||
| Net asset value per share of common stock at period end (in dollars per share) |
Loading...
